Basil Oied Mohemed Salih
Department of Clinical Biochemistry, College of Medicine, University of Baghdad, Baghdad

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

SERUM AND SEMINAL FLUID (RANKL) AND OSTEOPROTEGERIN LEVELS IN THE DIFFERENTIATION OF MALES WITH ASTHENOZOOSPERMIA Osama Ali Layih; Basil Oied Mohemed Salih
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 32 No. 3 (2026)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v32i3.2704

Abstract

Asthenozoospermia is defined as diminished sperm motility and is frequently observed in infertile males. This study was designed to examine the potential roles of receptor activator of nuclear factor of kappa-beta ligand (RANKL) and osteoprotegerin (OPG) in the development of asthenozoospermia, a subtype of male infertility. This case-control study was conducted at the infertility center of Al-Batool Teaching Hospital in Diyala Governorate, Iraq, in collaboration with the Department of Biochemistry, College of Medicine, University of Baghdad, between April 2024 and January 2025. The study enrolled 59 male subjects aged 20-55 years, who were categorized into two groups based on seminal fluid analysis: a normozoospermic group (n=29), which served as the control, and an asthenozoospermic group (n=30). Investigations included serum and seminal fluid measurements of parameters using enzyme-linked immunosorbent assays. The results showed that RANKL levels in both seminal plasma and serum were significantly increased, whereas OPG levels in both fluids were significantly decreased in the asthenozoospermic group compared with the normozoospermic group (p < 0.001 for all comparisons). The reservoir operating characteristics analysis revealed that seminal fluid and serum OPG demonstrated excellent diagnostic capability in distinguishing asthenozoospermic infertile subjects. The study suggests that seminal and serum OPG levels, and, to a lesser extent, serum RANKL, could serve as a new biomarker for differentiating asthenozoospermic subjects and could be used as a confirmatory (or alternative) test to seminal fluid analysis in such patients.
The Value of Cardiac Troponin I and Midkine in Predicting Coronary Artery Obstruction Severity in Chronic Coronary Syndromes (CCS) Moayed Basheer Hamid; Amal Abbas Hammoodi; Basil Oied Mohemed Salih; Ameen Al-Alwany
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 32 No. 3 (2026)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v32i3.2709

Abstract

High-sensitive cardiac troponin I (hs-cTnI) is a recognized marker of myocardial injury in acute coronary syndromes, but its utility in chronic coronary syndromes (CCS) remains unclear. Midkine (MK), a heparin-binding growth factor, plays a role in inflammation and vascular remodeling in atherosclerosis. This cross-sectional study aimed to evaluate the predictive value of serum hs-cTnI and MK in determining the severity of coronary artery obstruction in patients with CCS. The study included 125 subjects undergoing coronary angiography (CAG) at the Iraqi Center of Heart Disease/ Medical City/Baghdad, from March to December 2024. Subjects were classified into three groups based on CAG findings: no CAD, 1- or 2-vessel disease, and 3-vessel or left main disease. Serum levels of hs-cTnI and MK were measured using enzyme-linked immunosorbent assay (ELISA) in the laboratories of Department of Biochemistry/College of Medicine/ Baghdad University. Median serum levels of both biomarkers differed significantly across all groups. Receiver operating characteristic curve analysis demonstrated good diagnostic performance for both biomarkers in differentiating moderate (Group II) from severe disease (Group III). For hs-cTnI, a cutoff of 354.4 pg/mL yielded 90% sensitivity and 92% specificity; for MK, a cutoff of 2.75 ng/mL yielded 90% sensitivity and 85% specificity. Logistic regression revealed that the two biomarkers together explained 75% of the variance in CAD severity. Combining the two markers offered a slight improvement in diagnostic accuracy compared to using either alone. In conclusion, serum hs-cTnI and MK levels may help predict CAD severity in CCS and support early risk stratification before CAG.